Skip to main content

Table 4 Treatment-related Adverse Events That Occurred in ≥10% of Patients

From: Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

TRAE Patients Treated With Lenvatinib 24 mg Once Daily (N = 26)
Patients with any-grade TRAE, n (%) 26 (100)
Patients with any TRAE ≥ grade 3, n (%) 16 (61.5)
Preferred term, n (%) Any grade Grade 3 or 4
Hypertension 22 (84.6) 10 (38.5)
Dysphonia 16 (61.5) 0
Palmar-plantar erythrodysesthesia syndrome 15 (57.7) 3 (11.5)
Proteinuria 15 (57.7) 3 (11.5)
Thrombocytopenia 13 (50.0) 1 (3.8)
Decreased appetite 12 (46.2) 0
Fatigue 12 (46.2) 0
Hypothyroidism 12 (46.2) 0
Decreased weight 6 (23.1) 0
Diarrhea 6 (23.1) 0
Anemia 5 (19.2) 1 (3.8)
Malaise 5 (19.2) 0
Nausea 5 (19.2) 0
Peripheral edema 5 (19.2) 0
Myalgia 4 (15.4) 0
Stomatitis 4 (15.4) 0
Alopecia 3 (11.5) 0
Constipation 3 (11.5) 0
Epistaxis 3 (11.5) 0
Headache 3 (11.5) 0
Rash 3 (11.5) 1 (3.8)
Upper abdominal pain 3 (11.5) 0
  1. TRAE treatment-related adverse event
\